Ahn Sung-Min, Goode Robert J A, Simpson Richard J
Joint Proteomics Laboratory, Ludwig Institute for Cancer Research & theWalter and Eliza Hall Institute of Medical Research, Melbourne, Australia.
Proteomics. 2008 Dec;8(23-24):4946-57. doi: 10.1002/pmic.200800312.
Stem cells (SCs) are defined by their combined abilities to both self-renew indefinitely in vitro and differentiate into adult cell types. One of the major driving forces of SC research is that SCs may provide a potentially unlimited source for cell-replacement therapies in regenerative medicine. However, the identification of SCs and their progenies at different stages, and the success of cell-replacement therapies, which form the basis of SC engineering, will depend on the ability to characterize and ultimately isolate homogeneous primary stem or progenitor cell populations to a large degree. Furthermore, the recent identification of cancer stem cells (CSCs) opens a new avenue for developing novel therapeutic strategies by targeting a specific subset of cancer cells with self-renewal and proliferation capacity. Crucial to these tasks will be the discovery of novel plasma membrane-associated SC markers. In this review, we focus on the seminal contribution that membrane proteomics could make to further clinical applications of SCs by providing tools for purification and identification of SCs and their progenies at each stage of differentiation, as well as, to understand the underlying mechanisms of SC differentiation. The need to standardize biological SC models before embarking on international SC proteomics efforts is discussed.
干细胞(SCs)的定义是它们在体外具有无限自我更新以及分化为成体细胞类型的综合能力。干细胞研究的主要驱动力之一在于,干细胞可能为再生医学中的细胞替代疗法提供潜在的无限细胞来源。然而,不同阶段干细胞及其子代的鉴定,以及构成干细胞工程基础的细胞替代疗法的成功,在很大程度上取决于对均一的原代干细胞或祖细胞群体进行表征并最终分离的能力。此外,癌症干细胞(CSCs)的最新发现为开发新的治疗策略开辟了一条新途径,即通过靶向具有自我更新和增殖能力的特定癌细胞亚群。对于这些任务而言,关键在于发现新的与质膜相关的干细胞标志物。在本综述中,我们重点关注膜蛋白质组学通过提供工具来纯化和鉴定干细胞及其在分化各阶段的子代,以及理解干细胞分化的潜在机制,从而对干细胞的进一步临床应用可能做出的开创性贡献。我们还讨论了在开展国际干细胞蛋白质组学研究之前规范生物干细胞模型的必要性。